Forward Therapeutics

Biotech · Private

Small-molecule therapeutics for chronic inflammatory disorders

Claim this profile

Follows are private to you and power your alerts

Updated · forward-tx.com

Sector
Biotech
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
7
33 pending · first 2022
Rank in peer group#213 of 1462

Capital timeline

No federal awards or Form D filings are on record for this company.

Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.

Checked: SEC EDGAR Form D through Aug 28, 2026; SBIR and STTR awards through Jul 3, 2026; USAspending contract awards

Founder? Add funding context

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1079INTERO BIOSYSTEMS INC.——
1080EVOQUANT LLC——
1081Zivo Bioscience, Inc.—$9.1M
1082Forward Therapeutics——
1083BIOHELIX CORPORATION——
1084LAMASSU BIO INC——
1085RERX THERAPEUTICS, INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

No people are linked to this company yet.

People appear here when they are named as related persons in the company's own Form D filings. We don't infer people from social profiles.

Checked: SEC EDGAR Form D related persons through

Patents

USPTO · 7 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.